IZBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(5 years from now) | |
| US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(5 years from now) | |
| US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
| US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(6 years from now) | |
Izba is owned by Novartis.
Izba contains Travoprost.
Izba has a total of 4 drug patents out of which 0 drug patents have expired.
Izba was authorised for market use on 15 May, 2014.
Izba is available in solution/drops;ophthalmic dosage forms.
The generics of Izba are possible to be released after 10 October, 2029.
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of IZBA before it's drug patent expiration?
More Information on Dosage
IZBA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic